Skip to search formSkip to main contentSkip to account menu

ILX295501

Known as: ILX 295501, ILX-295501 
ILX-295501 is a novel sulfonylurea compound that has demonstrated in-vivo antitumor activity against a broad spectrum of solid tumors.
National Institutes of Health

Related topics

Related topics

2 relations
LY 295501

Broader (1)

Sulfonylurea Compounds

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2007
2007
Value of lambda, ×’ for crank-nicolson scheme on solving diffusion equation
The main purpose of this study is to investigate if a specific value of lambda, ×’. = k(I”t)) exists where M, I”t , I”x, k, p and… 
2003
2003
A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies.
PURPOSE This study was conducted to assess the feasibility of administering the oral diarylsulfonylurea (DSU) ILX-295501 on a… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)